Andriy O Samokhin1, Steven Hsu2, Paul B Yu3, Aaron B Waxman4, George A Alba5, Bradley M Wertheim4, C Danielle Hopkins2, Frederick Bowman1, Richard N Channick5, Ivana Nikolic6, Mariana Faria-Urbina4, Paul M Hassoun7, Jane A Leopold3, Ryan J Tedford8, Corey E Ventetuolo9, Peter J Leary10, Bradley A Maron11. 1. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 3. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 4. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 5. Division of Pulmonary and Critical Care Medicine. 6. Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts. 7. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 8. Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina. 9. Division of Pulmonary, Critical Care & Sleep Medicine, Departments of Medicine and Health Services, Policy and Practice, Brown University, Providence, Rhode Island. 10. Division of Pulmonary, Critical Care & Sleep Medicine, University of Washington, Seattle, Washington. 11. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: bmaron@partners.org.
Abstract
BACKGROUND: Pulmonary arterial hypertension (PAH) is a highly morbid disease characterized by elevated pulmonary vascular resistance (PVR) and pathogenic right ventricular remodeling. Endothelial expression of the prometastatic protein NEDD9 is increased in fibrotic PAH arterioles, and NEDD9 inhibition decreases PVR in experimental PAH. We hypothesized that circulating NEDD9 is increased in PAH and informs the clinical profile of patients. METHODS: Clinical data and plasma samples were analyzed retrospectively for 242 patients from 5 referral centers (2010-2017): PAH (n = 139; female 82%, 58 [48-67] years), non-PAH pulmonary hypertension (PH) (n = 54; female 56%, 63.4 ± 12.2 years), and dyspnea non-PH controls (n = 36; female 75%, 54.2 ± 14.0 years). RESULTS: Compared with controls, NEDD9 was increased in PAH by 1.82-fold (p < 0.0001). Elevated NEDD9 correlated with PVR in idiopathic PAH (ρ = 0.42, p < 0.0001, n = 54), connective tissue disease (CTD)-PAH (ρ = 0.53, p < 0.0001, n = 53), and congenital heart disease-PAH (ρ = 0.68, p < 0.0001, n = 10). In CTD-PAH, NEDD9 correlated with 6-minute walk distance (ρ = -0.35, p = 0.028, n = 39). In contrast to the PAH biomarker N-terminal pro-brain natriuretic peptide (n = 38), NEDD9 correlated inversely with exercise pulmonary artery wedge pressure and more strongly with right ventricular ejection fraction (ρ = -0.41, p = 0.006, n = 45) in a mixed population. The adjusted hazard ratio for lung transplant-free survival was 1.12 (95% confidence interval [CI], 1.02-1.22, p = 0.01) and 1.75 (95% CI, 1.12-2.73, p = 0.01) per 1 ng/ml and 5 ng/ml increase in plasma NEDD9, respectively, by Cox proportional hazard model. CONCLUSIONS: In PAH, plasma NEDD9 is increased and associates with key prognostic variables. Prospective studies that include hard end points are warranted to validate NEDD9 as a novel PAH biomarker. Published by Elsevier Inc.
BACKGROUND:Pulmonary arterial hypertension (PAH) is a highly morbid disease characterized by elevated pulmonary vascular resistance (PVR) and pathogenic right ventricular remodeling. Endothelial expression of the prometastatic protein NEDD9 is increased in fibrotic PAH arterioles, and NEDD9 inhibition decreases PVR in experimental PAH. We hypothesized that circulating NEDD9 is increased in PAH and informs the clinical profile of patients. METHODS: Clinical data and plasma samples were analyzed retrospectively for 242 patients from 5 referral centers (2010-2017): PAH (n = 139; female 82%, 58 [48-67] years), non-PAHpulmonary hypertension (PH) (n = 54; female 56%, 63.4 ± 12.2 years), and dyspnea non-PH controls (n = 36; female 75%, 54.2 ± 14.0 years). RESULTS: Compared with controls, NEDD9 was increased in PAH by 1.82-fold (p < 0.0001). Elevated NEDD9 correlated with PVR in idiopathic PAH (ρ = 0.42, p < 0.0001, n = 54), connective tissue disease (CTD)-PAH (ρ = 0.53, p < 0.0001, n = 53), and congenital heart disease-PAH (ρ = 0.68, p < 0.0001, n = 10). In CTD-PAH, NEDD9 correlated with 6-minute walk distance (ρ = -0.35, p = 0.028, n = 39). In contrast to the PAH biomarker N-terminal pro-brain natriuretic peptide (n = 38), NEDD9 correlated inversely with exercise pulmonary artery wedge pressure and more strongly with right ventricular ejection fraction (ρ = -0.41, p = 0.006, n = 45) in a mixed population. The adjusted hazard ratio for lung transplant-free survival was 1.12 (95% confidence interval [CI], 1.02-1.22, p = 0.01) and 1.75 (95% CI, 1.12-2.73, p = 0.01) per 1 ng/ml and 5 ng/ml increase in plasma NEDD9, respectively, by Cox proportional hazard model. CONCLUSIONS: In PAH, plasma NEDD9 is increased and associates with key prognostic variables. Prospective studies that include hard end points are warranted to validate NEDD9 as a novel PAH biomarker. Published by Elsevier Inc.
Authors: Laurent Calvier; Ekaterina Legchenko; Lena Grimm; Hannes Sallmon; Adam Hatch; Brian D Plouffe; Christoph Schroeder; Johann Bauersachs; Shashi K Murthy; Georg Hansmann Journal: Heart Date: 2016-03 Impact factor: 5.994
Authors: Roham T Zamanian; Haley Hedlin; Paul Greuenwald; David M Wilson; Joshua I Segal; Michelle Jorden; Kristina Kudelko; Juliana Liu; Andrew Hsi; Allyson Rupp; Andrew J Sweatt; Rubin Tuder; Gerald J Berry; Marlene Rabinovitch; Ramona L Doyle; Vinicio de Jesus Perez; Steven M Kawut Journal: Am J Respir Crit Care Med Date: 2018-03-15 Impact factor: 21.405
Authors: Johan M Lorenzen; Nils Nickel; Robert Krämer; Heiko Golpon; Volker Westerkamp; Karen M Olsson; Hermann Haller; Marius M Hoeper Journal: Chest Date: 2010-10-14 Impact factor: 9.410
Authors: Andriy O Samokhin; Thomas Stephens; Bradley M Wertheim; Rui-Sheng Wang; Sara O Vargas; Lai-Ming Yung; Minwei Cao; Marcel Brown; Elena Arons; Paul B Dieffenbach; Jason G Fewell; Majed Matar; Frederick P Bowman; Kathleen J Haley; George A Alba; Stefano M Marino; Rahul Kumar; Ivan O Rosas; Aaron B Waxman; William M Oldham; Dinesh Khanna; Brian B Graham; Sachiko Seo; Vadim N Gladyshev; Paul B Yu; Laura E Fredenburgh; Joseph Loscalzo; Jane A Leopold; Bradley A Maron Journal: Sci Transl Med Date: 2018-06-13 Impact factor: 17.956
Authors: Bradley M Wertheim; Yi-Dong Lin; Ying-Yi Zhang; Andriy O Samokhin; George A Alba; Elena Arons; Paul B Yu; Bradley A Maron Journal: PLoS One Date: 2019-02-27 Impact factor: 3.240
Authors: Sean Agbor-Enoh; Michael A Solomon; Samuel B Brusca; Jason M Elinoff; Yvette Zou; Moon Kyoo Jang; Hyesik Kong; Cumhur Y Demirkale; Junfeng Sun; Fayaz Seifuddin; Mehdi Pirooznia; Hannah A Valantine; Carl Tanba; Abhishek Chaturvedi; Grace M Graninger; Bonnie Harper; Li-Yuan Chen; Justine Cole; Manreet Kanwar; Raymond L Benza; Ioana R Preston Journal: Circulation Date: 2022-08-25 Impact factor: 39.918
Authors: Brandon S Peplinski; Brian A Houston; David A Bluemke; Steven M Kawut; Todd M Kolb; Richard A Kronmal; Joao A C Lima; David D Ralph; Samuel G Rayner; Zachary L Steinberg; Ryan J Tedford; Peter J Leary Journal: J Card Fail Date: 2021-04-17 Impact factor: 6.592